

**Paediatric Cancers at Butare University Teaching Hospital in Rwanda.**

M. Makanga, M.A. Ayinkamiye, L. Ngendahayo, I. Kakande

Butare University Teaching Hospital, NUR, Rwanda

Correspondance to: Dr Makanga Martine, mail: mmaka1@yahoo.fr

**Background:** Cancer is an important cause of mortality in many of the economically developed nations of the world. More than 10% of all deaths in children below 15 years of age are caused by malignant diseases in developed countries. In the developing world, childhood cancers are yet to be recognized as a major pediatric illness due to several other competing causes of death like diarrheal illness and respiratory illness.

**Methods:** A descriptive retrospective study of children admitted for cancer in Butare Teaching Hospital over a 7 years period (January 1999-December 2005) was carried out. The study population included 36 children aged 0-15 years admitted with cancer at Butare university teaching Hospital. Data was analyzed using Epi data, SPSS11,5 computer programs.

**Results:** The average age of our patients was 5.9 years with the youngest patient being 5 month old. The peak incidence of cancer was found in the 0-5 years age group and accounted for 21 patients (58, 3%). The Male to Female sex ratio was 1.7: 1. The most common types of cancer were: Burkett's lymphoma, Non-Hodgkin Lymphoma and Hodgkin's Lymphoma. Treatment included surgery for 17 patients (47.2%), chemotherapy for 4 patients (11.1%), surgery combined with post-operative chemotherapy for 1 patient (2.7%), the association of pre-operative chemotherapy + surgery + post-operative chemotherapy for 1 patient (2.7%) and palliative care for 13 patients (36.1%). The average length of hospital stay was 36.6 days ranging from 2 to 510 days. The hospital mortality rate was 27.7%.

**Recommendation:** The creation of an oncology department and a National cancer Register are recommended.

- Presented at Association of Surgeons of East Africa Conference in Mombasa, Kenya- Dec 6, 2007.

### Introduction

Although, Cancer is rare in children aged less than 15 years<sup>1</sup>, it represents a main concern for parents, families, and health professionals to care for children affected with cancer. The problems confronting Paediatric oncology in Africa are many. They are linked to:

- Lack of common strategy and policies concerning detection, prevention, and treatment of cancer patients
- Insufficient specialized human resources,
- Absence of referral cancer centers,
- Unavailability of antimetabolic drugs and radiotherapy,
- Lack of financial resources
- Patients consulting at late stage of cancer.

These lead to low survival and cure rates: The patients' survival at 5 years is  $\leq 50\%$  in developing world whereas cure rates in developed countries represent 75-80 %<sup>1</sup>. In Rwanda there is no possibility of effective, efficient management of cancer after diagnosis is confirmed for lack of an established oncology Department. A review of literature shows that no specific study on cancer in children has been reported from Rwanda. It was with such background that a study was undertaken on childhood cancers in Butare university Teaching Hospital.

### Results

During 7 years period of our study, there were 20,171 admitted patients in the five departments of Paediatric, Surgery, ENT, Ophthalmology and Stomatology of whom 36 (0.18%) patients had childhood cancer. Table 1 shows the annual distribution of

children with cancer in the 7 years. Figure 1 shows the age distribution. The age group 0 to 5 years was the most affected accounting for 21 (58.3%) of the cases. The youngest patient was aged 5 months (Figure 1). Twenty three patients were males and 13 were females. (Male: female ratio = 1.8: 1). Table 2 shows the distribution of cancers according to age groups. The 0 – 5 year age group accounted for 21 (58.3%) of the cases. The commonest malignancy in this age group was Burkitt's lymphoma. Burkitt's Lymphomas were accounted for a third (33.3%) of the tumours in the 0 – 5 age group (Table 2). The commonest type in the 6 – 10 years age group was non Hodgkin's lymphoma. In males, Burkitt's lymphoma accounted for 14 (60.9%) of cancers while in females the tumours were more evenly distributed (Table 3). Table 4 shows the location of the cancers. Most tumours were located in accessible sites for the guardians or patients as well as the health workers.

Clinical features on the 5 main cancers were many. A swelling or mass was the predominant presentation. Other features included pyrexia, peripheral lymphadenopathy, hepatomegaly, splenomegaly, weight loss, pallor and abdominal tenderness. Others signs and symptoms deferred from one type of cancer to the other. The site of tumour varied. Burkitt's lymphoma was located in maxilla

and mandible (8 cases over 10:80%). Thirty four patients had confirmed histological diagnosis. Two patients had diagnosis confirmed by bone marrow examination.

Tables 6 and 7 summarize the mode of treatment received by the children. One form of surgery or the other was performed in 17 (47.2%) of the patients and included tumour excision, limb amputation, Nephrectomy, eye exenteration and others. Only 4 patients (11.1%) benefited from chemotherapy. Palliative treatment was offered to 13 patients with advanced disease. Palliative care included analgesics, intravenous fluids, blood transfusion, and nursing. Radiotherapy is not offered in Rwanda and therefore none of the patients had such a modality of treatment. Only 4 patients had chemotherapy. Two patients with NHML received a combination of Endoxan 40mg /m<sup>2</sup> + Vincristine + Methotrexate + Prednisolone for 2 sessions. One patient with Burkitt's Lymphomareceived 3 sessions of Endoxan 40mg/m<sup>2</sup> and Prednisolone 2mg/ kg. One patient with Acute Lymphoid Leukemia had Endoxan 40mg/m<sup>2</sup> + Vincristine1,5mg/m<sup>2</sup> + L-Asparaginase+ Methotrexate + Prednisolone 2 mg/kg.

The average length of stay in hospital was 36.6% days with the extremes of 2 days and 510 days.

**Table 1.** Patients' Distribution According to Years of Admission.

Year	Department					Total
	Surgery	Paediatric	ENT	Ophthalmology	Stomatology	
1999	2	1	0	0	0	3
2000	0	0	2	2	0	4
2001	2	5	3	0	0	10
2002	1	3	1	1	0	6
2003	0	2	2	0	0	4
2004	1	1	1	0	0	3
2005	1	2	2	0	1	6
<b>Total</b>	<b>7</b>	<b>14</b>	<b>11</b>	<b>3</b>	<b>1</b>	<b>36</b>

**Table 2.** Age Distribution and type of cancer.

Type of cancer	Age group (years)			Total
	0 to 5	6 to 10	11 to 15	
*NHL	0	6	1	7
Burkitt's Lymphoma	7	3	0	10
Hodgkin's Lymphoma	2	0	2	4
Retinoblastoma	2	0	0	2
Rhabdomyosarcoma	2	0	0	2
Nephroblastoma	2	0	0	2
Neuroblastoma	1	0	0	1
Osteosarcoma	0	0	1	1
Non-specified Sarcoma	1	0	0	1
Malignant Schwannoma	1	0	0	1
Hepatoblastoma	1	0	0	1
Malignant Mélanoma	0	1	0	1
**AcLL	2	0	1	3
<b>Total</b>	<b>21</b>	<b>10</b>	<b>5</b>	<b>36</b>

\*NHL = Non Hodgkin Lymphoma, \*\*Ac LL = Acute Lymphoid Leukemia

**Table 3.** Patient Distribution According to Type of Cancer and Sex.

Type of cancer	Sex		Total	M :F Sex Ratio
	Male	Female		
*NHL	6	1	7	6 :1
Burkitt' Lymphoma	8	2	10	4 :1
Hodgkin's Lymphoma	3	1	4	3 :1
Retinoblastoma	0	2	2	0 :2
Rhabdomyosarcoma	1	1	2	1 :1
Nephroblastoma	1	1	2	1 :1
Neuroblastoma	1	0	1	1 :0
Osteosarcoma	0	1	1	0 :1
Non-specified Sarcoma	0	1	1	0 :1
Malignant Schwannoma	0	1	1	0 :1
Hepatoblastoma	0	1	1	0 :1
Malignant Melanoma	1	0	1	1 :0
**Ac LL	2	1	3	2 :1
<b>Total</b>	<b>23</b>	<b>13</b>	<b>36</b>	<b>1.8 :1</b>


\*NHL = Non Hodgkin Lymphoma, \*\*Ac LL = Acute Lymphocytic Leukemia

Patients' complications were: infection, bonemarrow aplasia, blindness, nausea, vomiting, observed in 4 (27.7%) patients who had Burkiitt's Lymphoma, acute leukemia or Hodgkin lymphoma under chemotherapy.

The outcome at discharge varied: 11 patients (30.5%) improved, 15 patients

(41.6%) didn't improve that is general state remained the same or worsened. Ten patients died in hospital (27.8% mortality)

and included 1 patient who had surgery, all 4 patients treated with chemotherapy and 5 patients managed with palliative care alone. The patients' follow up was difficult, only 3 patients over 36 was seen 1 month later.



**Figure1.** Group age distribution

**Table 4.** Sites of Cancers.

Type of cancer	Site of Tumour	Number
Burkitt' Lymphoma	Retro-auricular	1
	Abdominal (right kidney)	1
	Supra maxillar	6
	Mandibular	2
	<b>Total</b>	<b>10</b>
NHL	Supra maxillar	2
	Right tibia	1
	Cervical nodes	2
	Buccal cavity	1
	Mandibular	1
	<b>Total</b>	<b>7</b>
Hodgkin' Lymphoma	Neck lymphonodes	<b>4/4</b>
Rhabdomyosarcoma	Cervical	1
	bladder	1
	<b>Total</b>	<b>2</b>
Nephroblastoma	Right kidney	<b>2/2</b>
Retinoblastoma	Right eye	1
	Left eye	1
	<b>Total</b>	<b>2</b>

**Table 5.** Histological Types of Cancer in Children

Type of Cancer	Number	%
NHL	7	19.4
Burkitt's Lymphoma	10	27.7
Hodgkin's Lymphoma	4	11.1
Retinoblastoma	2	5.5
Rhabdomyosarcoma	2	5.5
Nephroblastoma	2	5.5
Neuroblastoma	1	2.7
Osteosarcoma	1	2.7
Non identified Sarcoma	1	2.7
Malignant Schwannoma	1	2.7
Hepatoblastoma	1	2.7
Malignant Melanoma	1	2.7
Acute Lymphoid Leukemia	3	8.3
<b>Total</b>	<b>36</b>	<b>100</b>

**Table 6.** Patients Distribution According Treatment

Treatment		Number	%
Surgery	Tumor excision	12	33.3
	Limb amputation	1	2.7
	Nephrectomy	2	5.5
	Eye exenteration	2	5.5
Chemotherapy	Cyclophosphamide+Vincristine+Methotrexate + Prednisolone	2	5.5
	Cyclophosphamide+Prednisolone	1	2.7
	Cyclophosphamide + Vincristine+L-Asparaginase + Methotrexate + Prednisolone	1	2.7
Surgery Chemotherapy	Limb amputation+Cyclophosphamide+ Vincristine + Prednisolone in post-operative	1	2.7
Palliative traitement	Analgesics, ATB, intravenous fluids, blood transfusion, antipyretics, etc.	13	36.1
Chemotherapy- Surgery- Chemotherapy	Cyclophosphamide + Vincristine+Prednisolone + Nephrectomy+ Cyclophosphamide + Vincristine + Adriblastine + Prednisolone.	1	2.7
<b>Total</b>		<b>36</b>	<b>100</b>

**Tableau 7.** Patients outcome versus type of cancer

Type of cancer	Total			
	Improved	No Improvement	Died in hospital	Total
*NHL	2	3	2	7
Burkitt's Lymphoma	1	7	2	10
**HL	1	2	1	4
Acute leukemia	0	0	3	3
Retinoblastoma	2	0	0	2
Rhabdomyosarcoma	0	1	1	2
Nephroblastoma	2	0	0	2
Others	3	2	1	6
Neuroblastoma	1	0	0	1
<b>Total</b>	<b>11</b>	<b>15</b>	<b>10</b>	<b>36</b>

\*NHL = Non Hodgkin's Lymphoma

\*\*HL = Hodgkin's Lymphoma

## Discussion

Cancer is a subject of constant preoccupation in the world<sup>1</sup>. It is rare in children aged less than 15 years, it represents 1-3% of all tumors in the population<sup>2,3,4,5,6,7</sup>. In France, each year 1800 to 2000 new cases of cancer in children are registered<sup>1,3,8</sup>. In Switzerland, 220 children; in Belgium less than 300 children are affected each year. This study confirmed that cancer in children is a rare . Our hospital prevalence was similar to that reported by other sauthors<sup>3,5,6,9</sup>. The disease predominantly affects young children in the

0 -5 years age group. Other studies have reported similar findings.<sup>1,2,6</sup>.

The clinical presentation in our children was in agreement with previous literature<sup>10,3,7,11,12</sup>. The patients' management and outcome in our series significantly differed from what is reported by other centres with established surgical oncology departments<sup>1,3,5,13</sup>. In our study, surgical treatment, being the only available form of treatment for cancer in the country, was offered to many cases.. Antimitotics drugs were not always available, and they were too expensive for ordinary Rwandese patients. There is no Radiotherapy Centre in

the country nor is there any well established chemotherapy unit. This unfortunate situation contributed to the poor outcome and bad prognosis of our patients. The need for establishing such centres in the country is overwhelming.

### Conclusion

Our findings showed that the clinical features and pathological types of cancers seen among children in Rwanda were similar to what has been reported by other authors in the literature. But the difference was that most of our patients were admitted in advanced stage of the disease. Because of lack of an Oncology Department, absence of appropriate drugs for chemotherapy, and lack of radiotherapy and palliative Medicine, our patients' management and outcome were poor. There is an urgent need to improve our Hospital in establishing proper structure and facilities to attend to cancer patients efficiently.

### Recommendations

- We appeal to the Ministry of Health to establish an oncology department in Rwanda and to ensure that chemotherapy, radiotherapy, palliative medicine and counseling services for patients affected with cancer are available.
- A national cancer register should be opened.
- Personnel should be trained to form multidisciplinary teams and specialists for the care of cancer patients.
- Diagnostic facilities for cancer should be improved to make diagnosis of cancer quick and accurate.

### References

1. Desandes.E., Clavel.J., Berger.C., Bernard.J.L., Blouin.P., Lumley.L. et al. Incidence des cancers de l'enfant en France, 1990-1999. Bulletin épidémiologique hebdomadaire 2005, 32,161-4.

2. Les tumeurs solides malignes de l'enfant à Brazzaville : Aspects épidémiologiques et anatomopathologiques. <http://WWW.Pathexo.Fr/pdf/2004.2/T97-2-2511-2p.pdf>
3. Dominique Plantaz : Particularités épidémiologiques des cancers chez l'enfant. Faculté de Médecine de Grenoble, Décembre, 2003.
4. Le cancer chez l'enfant. [http://www.esante.be/be/magazine\\_sante/sante\\_enfants\\_adolescents/cancer\\_enfant-6108-971-art.htm](http://www.esante.be/be/magazine_sante/sante_enfants_adolescents/cancer_enfant-6108-971-art.htm)
5. Anne d'Andon, Gilles Vassal, Olivier Hartmann. Les tumeurs osseuses. Institut Gustave-Roussy, Février, 2004.
6. Laila Hessissen : Le traitement du cancer chez l'enfant. Rabat, Novembre 2001.
7. Le cancer de l'enfant. <http://WWW.ands.dz/sacp/donnees/onco002.htm>
8. Les cancers chez l'enfant. <http://WWW.la-sfop.com/sfop.nsf/pgLCE?Openpage&AutoFramed>
9. Phillipe Abimelec. Médecine et chirurgie de la peau, des ongles et des cheveux, Novembre 2000.
10. J'ai vaincu le cancer. <http://www.UICC.org/fileadmin/aser-uploadUICC/wcd/leafletA4-fr.pdf>
11. Baruchel.A ; Benkritly.A ; Benzohra.A ; Caulin.C ; Chastagner.P ; Defrance.R ; et al. Hématocancérologie pédiatrique. Table Ronde no4. Giens 2002.
12. Outtara.K., Daffes., Tembely.Y.A. Les tumeurs du rein dans la pratique de l'urologue au Mali. (A propos de 17 cas). Médecine d'Afrique Noire 1993, 40(4), 253-6
13. KA. A.S, Imbert. P., Moreira. C. et al: Epidémiologie et pronostic des affections malignes de l'enfant 2003, 63, 521-26.